DOJ’s New Policy Saves $1.6M on Transgender Procedures for Inmates

UPDATE: The U.S. Department of Justice has just announced a new policy expected to save taxpayers over $1.65 million previously allocated for transgender medical procedures in federal prisons. This significant shift in policy, issued on February 19, 2024, will eliminate federal funding for gender-affirming surgeries and related medical treatments for transgender inmates.

This urgent change comes as the Biden administration reverses previous practices that had cost the Federal Bureau of Prisons (BOP) approximately $1.65 million annually. Of this amount, about $1.25 million was spent on hormone-replacement therapy, which included $130,000 specifically for testosterone suppressants and estrogen injections. With the new policy, the BOP will no longer be responsible for funding surgeries or providing hormonal treatments for inmates seeking to alter their appearance.

In a statement, a DOJ official emphasized that the new policy would prevent nearly $2 million from being spent on procedures deemed potentially harmful and a source of safety concerns within correctional facilities. The official stated,

“This policy considers that drastic treatment, like sex trait modification surgeries, are harmful to inmates.”

Previously, wardens were mandated to provide necessary medical modifications, but under the revised guidelines, the BOP will now prescribe antidepressants and psychotherapy to address underlying mental health issues associated with gender dysphoria. For inmates already undergoing hormone therapy, a taper plan will be implemented to gradually reduce doses, ensuring a safe withdrawal process.

The policy also removes access to non-medical accommodations funded by taxpayers, such as breast padding, chest binders, and makeup, which inmates previously received as part of their “social transitioning.” Any currently used items will be confiscated by prison staff, although inmates will still have options to purchase gender-specific clothing and cosmetics.

This decision has sparked criticism from advocates and lawmakers. California state Senator Scott Wiener condemned the policy as part of a “genocidal campaign against trans people.” In contrast, the DOJ maintains that the revised approach allows for individualized assessments to address the specific needs of each inmate while prioritizing safety and mental health.

As this policy takes effect, questions arise about the implications for the treatment of transgender inmates and the future of funding for medical needs within the BOP. Observers will be watching closely to see how this will shape the landscape of transgender rights within the federal prison system.

Stay tuned for further updates on this developing story as reactions unfold and potential impacts on inmates are assessed.